# Junta clínica — PT-pseudo_c39e94a13920 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c39e94a13920",
  "pid": "PT-pseudo_c39e94a13920",
  "task": 1,
  "psa": 12.4,
  "age": 67,
  "months": 3,
  "pirads": "3",
  "psad": 0.08,
  "psav": 1.58,
  "psap": 11.3,
  "vol": 149.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.58010316,
  "medhx": "Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "atorvastatin, rosuvastatin",
  "notes": "PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Chronic kidney disease",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "91 kg",
    "height": "178 cm",
    "bmi": "28.7",
    "bp": "128/89 mmHg",
    "hr": "70 bpm",
    "smoking": "Ex-smoker (19 pack-yr, quit 2016)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "03 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical review sought due to sustained PSA elevation and a previously positive biopsy result."
    },
    {
      "s": "History",
      "t": "A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history."
    },
    {
      "s": "Physical examination",
      "t": "DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Married",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "4 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c39e94a13920
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 12.4 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.58 ng/mL/yr
  - Prior PSA: 11.3 ng/mL
  - Prostate volume: 149.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.58010316 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: atorvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.

Vitals: weight 91 kg, height 178 cm, BMI 28.7, BP 128/89 mmHg, HR 70 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Clinical review sought due to sustained PSA elevation and a previously positive biopsy result.

History: A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history.

Physical examination: DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent.

Patient info: graphic designer; Married; Lives with partner; adult children visit weekly.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 4 units / week; exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.53
  uncertainty  +/- 0.16 epistemic (95% band 0.21-0.84); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 3, PSA 12.4, PSAD 0.08, age 67, DRE Normal -> BIOPSY (clear). He wrote: "AS for Intermediate risk PC in younger patient with very large prostate and only one biopsy procedure before. Needs confirmatory biopsy."
  2. distance 1.07: PI-RADS 3, PSA 7.7, PSAD 0.11, age 64, DRE Normal -> DEFER (borderline). He wrote: "Low risk PC with PSA <10. No red flags on biopsy or MRI, reasonably low PSA density. MRI finding minor and probably penetrated by systematic biopsy core (peripheral zone…"
  3. distance 2.08: PI-RADS 3, PSA 6.0, PSAD 0.13, age 58, DRE Normal -> DEFER (borderline). He wrote: "Need to know earlier MRI results. If stabile P3 lesion, no biopsy."

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, psa=noted, age=important, dre=noted, cspca=noted, vol=decisive, pirads=important, comorbidity=noted, psad=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines discuss the use of MRI and biopsy in the context of prostate cancer risk stratification. The guideline suggests that a stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled by the guideline because the guideline focuses on risk stratification based on MRI and PSA density thresholds, not on the prior biopsy status alone. The guideline does not provide a decisive rule that makes the prior positive biopsy status irrelevant when other variables are present.

WHAT WE STILL NEED
The guideline requires establishing the documented grade of the prior biopsy and the number and dates of biopsy sessions to determine the next step.
Prior biopsy status is documented as "Positive" on the panel, and the specific Gleason or ISUP grade and biopsy dates are not provided in the visible data.
The number of biopsy sessions and dates is not provided in the visible data.
Whether the patient is on a surveillance protocol with a confirmatory biopsy due is not provided in the visible data.
The MRI prose is not provided, which is necessary to assess if it compares against an earlier study.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on establishing the documented grade and history of the prior biopsy to determine the next step.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and whether it is compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend beyond the headline value?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy result grade (Gleason/ISUP), number of biopsy sessions, and surveillance plan?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented Gleason or ISUP grade and the number and dates of prior biopsy sessions?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
lesion size and zone, extraprostatic extension, and whether it is compared against an earlier study: Focal area noted in the right peripheral zone at the mid-gland level, spanning roughly 14 x 11 x 10 mm. No evidence of extraprostatic extension or seminal vesicle invasion. Compared with an earlier study: new.

psa_trend
serial PSA value trend beyond the headline value: Aug 2023: 2.2 ng/mL, Dec 2023: 3.4 ng/mL, Apr 2024: 5.2 ng/mL, Aug 2024: 8.0 ng/mL, Jan 2025: 12.4 ng/mL.

previous_notes
management context, including the prior biopsy result grade (Gleason/ISUP), number of biopsy sessions, and surveillance plan: August 2023 laboratory results recorded a PSA level of 7.1 ng/mL, marking a continuation of the initial borderline elevation observed earlier that year. Prompted a urological referral for multiparametric MRI and further risk stratification.

laboratory_results
full panel results, including free-PSA fraction, renal function, and haemoglobin: PSA: 12.4 ng/mL, Free PSA: 2.60 ng/mL, %Free PSA: 21%, Creatinine: 166 umol/L, eGFR: <60 mL/min/1.73m2, Haemoglobin: 14.9 g/dL.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes did not contain any information regarding the family history of prostate cancer.

WHAT THIS SUPPORTS
findings that argue FOR sampling this patient now:
PSA trend shows a clear upward trajectory leading to the current level of 12.4 ng/mL.
The mpMRI shows a PI-RADS 3 lesion with restricted diffusion, suggesting a focal area of concern.

findings that argue AGAINST sampling this patient now:
The prior biopsy result is documented as "Positive," and the previous notes do not specify the Gleason/ISUP grade or the number/dates of prior sessions.

WHERE THIS LEANS
The data strongly suggests that the critical missing information regarding the prior biopsy grade and surveillance plan must be obtained before a definitive decision can be made.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 12.40 ng/mL over 5 points spanning 17 months; velocity +7.21 ng/mL per year; doubling time about 7 months.
PROJECTION at 6 months: 21.9 ng/mL, conformal 95% band 6.3-76.4.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.61
  uncertainty  +/- 0.16 epistemic (95% band 0.30-0.92), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.53  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.61  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.94  (identical panel in the series)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, psa=noted, age=important, dre=noted, cspca=noted, vol=decisive, pirads=important, comorbidity=noted, psad=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—do not fully answer the moderator's questions. Specifically, the previous_notes do not contain the documented Gleason/ISUP grade or the number and dates of prior biopsy sessions, and the surveillance plan is not explicitly detailed.

ALIGNMENT WITH THE PANEL
The retrieved evidence does not directly overturn the PANEL-PROTOCOL's answer of BIOPSY, as the critical missing information regarding the prior biopsy grade and surveillance plan remains unaddressed by the retrieved data.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented Gleason or ISUP grade and the number and dates of prior biopsy sessions? Not answered by the retrieved documents.
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Not answered by the retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade and the surveillance plan are the most critical variables because the EAU guideline explicitly requires this information to determine the next step. The rising PSA trend and the PI-RADS 3 finding are important but secondary to the documented history of prior tissue diagnosis.

MY SUGGESTION TO THE CHAIR
Given that the critical information required by the guideline is missing, the record is not yet in a state to be decided according to the protocol. We must defer until the registrar retrieves the specific details regarding the prior biopsy grade and surveillance plan.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

A biopsy is recommended because the patient has a documented prior positive biopsy result, which is the critical factor determining the next step in management. This decision is supported by the combination of the rising PSA trend, which showed a trajectory to 12.4 ng/mL, and the PI-RADS 3 finding on MRI. The evidence converged on the need for further tissue diagnosis to establish the documented Gleason grade and surveillance plan.

What carried weight: bx=important, psa=noted, age=important, dre=noted, cspca=noted, vol=decisive, pirads=important, comorbidity=noted, psad=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
